Intelligence · Clinical Development
Pipeline search results
Programs matching “rituximab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 46 pipeline programs matching "rituximab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Severe Aplastic Anemia
1 trial -
Rituximab Paclitaxel Ruxolitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory Diffuse Large B-cell Lymphoma
1 trial -
Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
1 trial -
Zanubrutinib+Rituximab+Lenalidomide
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
bendamustine and rituximab
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
1 trial -
lenalidomide combined with rituximab
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
orelabrutinib combined with rituximab regimen
The First People's Hospital of Lianyungang
Marginal Zone Lymphoma(MZL)
1 trial -
rituximab
United Therapeutics Europe Ltd
Lymphoma
1 trial -
rituximab
Chinese University of Hong Kong
Systemic Lupus Erythematosus
1 trial -
rituximab
Children's Hospital of Fudan University
Lymphoproliferative Disorder
1 trial -
rituximab
Ultragenyx UK Limited
Purpura, Thrombocytopenic, Idiopathic
1 trial -
rituximab /Dexamethasone/cyclophosphamide
The First People's Hospital of Lianyungang
Treatment
1 trial -
20 mg/kg TRU-016 + Rituximab
Aptevo Therapeutics
Chronic Lymphocytic Leukemia
1 trial -
Loncastuximab tesirine and rituximab (Lonca-R)
ADC Therapeutics SA
Central Nervous System Lymphoma
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma Recurrent
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Carcinoma
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Hemophagocytic Lymphohistiocytosis
1 trial -
rituximab combined with corticosteroids
The First People's Hospital of Lianyungang
Primary Membranous Nephropathy
1 trial -
PCNSL-RMTEA
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenic Purpura
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.